RT Journal Article
SR Electronic
T1 Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20032011
DO 10.1101/2020.03.05.20032011
A1 Shona C. Moore
A1 Rebekah Penrice-Randal
A1 Muhannad Alruwaili
A1 Xiaofeng Dong
A1 Steven T. Pullan
A1 Daniel P. Carter
A1 Kevin Bewley
A1 Qin Zhao
A1 Yani Sun
A1 Catherine Hartley
A1 En-min Zhou
A1 Tom Solomon
A1 Michael B. J. Beadsworth
A1 James Cruise
A1 Debby Bogaert
A1 Derrick W. Crook
A1 David A. Matthews
A1 Andrew D. Davidson
A1 Zana Mahmood
A1 Waleed Aljabr
A1 Julian Druce
A1 Richard T. Vipond
A1 Lisa F. P. Ng
A1 Laurent Renia
A1 Peter J. M. Openshaw
A1 J. Kenneth Baillie
A1 Miles W. Carroll
A1 Malcolm G. Semple
A1 Lance Turtle
A1 Julian A. Hiscox
YR 2020
UL http://medrxiv.org/content/early/2020/03/08/2020.03.05.20032011.abstract
AB COVID-19 is a complex disease phenotype where the underlying microbiome could influence morbidity and mortality. Amplicon and metagenomic MinION based sequencing was used to rapidly (within 8 hours) identify SARS-CoV-2 and assess the microbiome in nasopharyngeal swabs obtained from patients with COVID-19 by the ISARIC 4C consortium.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.tghn.org Funding StatementThis work was supported by the United States Food and Drug Administration grant number HHSF223201510104C ‘Ebola Virus Disease: correlates of protection, determinants of outcome and clinical management’ amended to incorporate urgent COVID-19 studies. Awarded to J.A.H., A.D., D.A.M. and M.W.C. Recruitment, sample acquisition, transport, laboratory and management costs were supported by the Medical Research Council “Protocol for Severe Emerging Infection” grant number MC_PC_19025 awarded to J.K.B., M.G.S., and P.J.M.O. This work was supported by Research Center, King Fahad Medical City, Saudi Arabia grant number 019-003 ‘Elucidating the viral biology of MERS-CoV and the host response using high resolution sequencing’. Awarded to W.A. This work was supported by the Medical Research Council Discovery Medicine North Doctoral Training Partnership and directly funds the studentship of R.P.-R. This work was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England. Awarded to T.S. L.T. is a Wellcome Trust clinical career development fellow, supported by grant number 205228/Z/16/Z. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be obtained from the corresponding author by request